Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.49 |
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29400921 | 1.00 | MDM2 (0.55) | MDM2KMT2ATGM2TLR2MDM4 | |
| SCHEMBL178698 | 0.90 | KMT2A (0.66) | MDM2KMT2ATLR2MDM4TP53 | |
| SCHEMBL29401258 | 0.90 | KMT2A (0.66) | MDM2KMT2ATLR2MDM4TP53 | |
| SCHEMBL260631 | 0.90 | KMT2A (0.66) | MDM2KMT2ATLR2MDM4TP53 | |
| SCHEMBL29359997 | 0.90 | KMT2A (0.66) | MDM2KMT2ATLR2MDM4TP53 | |
| SCHEMBL178733 | 0.90 | KMT2A (0.66) | MDM2KMT2ATLR2MDM4TP53 | |
| SCHEMBL29528567 | 0.90 | KMT2A (0.66) | MDM2KMT2ATLR2MDM4TP53 | |
| SCHEMBL23056476 | 0.89 | KMT2A (0.58) | MDM2KMT2ATLR2MDM4TP53 | |
| SCHEMBL14071942 | 0.89 | KMT2A (0.58) | MDM2KMT2ATLR2MDM4TP53 | |
| SCHEMBL1738761 | 0.87 | KMT2A (0.56) | MDM2KMT2ATLR2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210053044-A1 | Redox Dehydration Coupling Catalysts and Methods Related Thereto | UNIV EMORY (US) | 2021-02-25 | — | — | US | disclosed |
| EP-1858538-B1 | MUCIN HYPERSECRETION INHIBITORS BASED ON THE STRUCTURE OF MANS AND METHODS OF USE | BIOMARCK PHARMACEUTICALS LTD (US) | 2019-03-27 | — | — | EP | disclosed |
| US-20180318818-A1 | Redox Dehydration Coupling Catalysts and Methods Related Thereto | EMORY UNIVERSITY (US) | 2018-11-08 | — | — | US | disclosed |
| US-9700881-B2 | Heterocyclic coupling catalysts and methods related thereto | EMORY UNIVERSITY (US) | 2017-07-11 | — | — | US | disclosed |
| WO-2017070157-A1 | REDOX DEHYDRATION COUPLING CATALYSTS AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2017-04-27 | — | — | WO | disclosed |
| US-9598463-B2 | Mucin hypersecretion inhibitors and methods of use | BIOMARCK PHARMACEUTICALS, LTD. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160243534-A1 | Heterocyclic Coupling Catalysts and Methods Related Thereto | EMORY UNIVERSITY (US) | 2016-08-25 | — | — | US | disclosed |
| US-20150274778-A1 | MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE | BIOMARCK PHARMACEUTICALS, LTD. | 2015-10-01 | — | — | US | disclosed |
| WO-2015054337-A1 | HETEROCYCLIC COUPLING CATALYSTS AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2015-04-16 | — | — | WO | disclosed |
| US-8907056-B2 | Mucin hypersecretion inhibitors and methods of use | BIOMARCK PHARMACEUTICALS, LTD. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8293870-B2 | Mucin hypersecretion inhibitors and methods of use | BIOMARCK PHARMACEUTICALS LTD (US) | 2012-10-23 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| EP-2399599-A2 | MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE | Biomarck Pharmaceuticals, Ltd. (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100197607-A1 | MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE | WILLIAMS, MASON L. | 2010-08-05 | — | — | US | disclosed |
| US-20090275520-A1 | MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE | WILLIAMS, MASON L. | 2009-11-05 | — | — | US | disclosed |
| US-7524926-B2 | Mucin hypersecretion inhibitors and methods of use | BIOMARCK PHARMACEUTICALS, LTD. (US) | 2009-04-28 | — | — | US | disclosed |
| CN-101146545-A | Mucin hypersecretion inhibitors based on the structure of MANS and methods of use | BIOMARCK PHARMACEUTICALS LTD (US) | 2008-03-19 | — | — | CN | disclosed |
| EP-1858538-A2 | MUCIN HYPERSECRETION INHIBITORS BASED ON THE STRUCTURE OF MANS AND METHODS OF USE | Biomarck Pharmaceuticals, Ltd. (US) | 2007-11-28 | — | — | EP | disclosed |
| US-20060205664-A1 | Mucin hypersecretion inhibitors and methods of use | WILLIAMS, MASON L. | 2006-09-14 | — | — | US | disclosed |
| WO-2006078899-A2 | MUCIN HYPERSECRETION INHIBITORS BASED ON THE STRUCTURE OF MANS AND METHODS OF USE | BIOMARCK PHARMACEUTICALS, LTD. (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160243534-A1 | Heterocyclic Coupling Catalysts and Methods Related Thereto | HAT1, CBR3, CBR1 | MDM2 1109/4885KMT2A 608/4885TGM2 925/4885 |
| US-20180318818-A1 | Redox Dehydration Coupling Catalysts and Methods Related Thereto | SCLY, TST, SELENOI | MDM2 1794/4885KMT2A 926/4885TGM2 402/4885 |
| US-20210053044-A1 | Redox Dehydration Coupling Catalysts and Methods Related Thereto | SCLY, TST, SQOR | MDM2 1683/4885KMT2A 1054/4885TGM2 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.